Latest news
Loading news…
APNAR Pharma
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 LowHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Chino, California, United States Founded 2014 11-50 employees For Profit
APNAR Pharma is a pharmaceutical company engaged in the licensing, manufacturing, and distribution of generic prescription drugs.
APNAR Pharma was acquired by Senores Pharmaceuticals in 2025 for $10M.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
1
Monthly Visits
Available in Pro Contacts
9
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 39
- IT spend
- $96K
Company Info
- Founded
- 2014
- Employees
- 11-50
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- News articles
- 4
- HQ
- Chino, California, United States
- Region
- Greater Los Angeles Area, Inland Empire, West Coast
- Exit date
- Dec 15, 2025
Signals & Scores
- Heat score
- Low
- Growth score
- Low
- Trend (7d)
- -0.1
- Trend (30d)
- 0
- Trend (90d)
- 4
Acquisitions by APNAR Pharma
Loading columns…
0 of 0Show
Page 1 / 1
9
professional contacts at APNAR Pharma
Contact execs at APNAR Pharma →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to APNAR Pharma
Loading news…
FAQs about APNAR Pharma
People who checked this page also checked these
Sectors APNAR Pharma invests & acquires in
Browse the full Acquirezy directory.